Physician profile
Ferid Osmanovic
NPI 1992976385
$2,195.91
in general payments reported to CMS, 2019-2025
23 companies · $580 in 2025
The $580 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $133 · 2021: $127 · 2022: $328 · 2023: $264 · 2024: $596 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $628.60 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $361.19 | 2021-2025 | |
| Amarin Pharma, INC. | $272.36 | 2019-2022 | |
| Novo Nordisk INC | $150.47 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $100.45 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $90.94 | 2022-2025 | Eliquis |
| Lilly USA, LLC | $90.12 | 2022-2025 | Mounjaro, Zepbound |
| Dynavax Technologies Corporation | $60.05 | 2022-2023 | Heplisav-B |
| Amgen INC. | $58.16 | 2023-2025 | Evenity, Prolia, Prolia |
| Alnylam Pharmaceuticals INC. | $55.64 | 2024-2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $54.31 | 2019 | |
| Abbott Laboratories | $49.11 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $25.00 | 2024 | |
| Amneal Pharmaceuticals LLC | $24.81 | 2022 | |
| Ardelyx, INC. | $24.07 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $22.89 | 2023 | Smartvest |
| Phathom Pharmaceuticals, INC. | $22.73 | 2024 | Voquezna |
| Gilead Sciences, INC. | $22.51 | 2021 | |
| Medtronic, INC. | $20.07 | 2025 | Minimed 780g |
| Kowa Pharmaceuticals America, INC. | $17.50 | 2024 | Zoryve |
| Dexcom, INC. | $16.63 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.47 | 2021 | |
| Merck Sharp & Dohme LLC | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferid Osmanovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.